Strengthening collaboration between safety information services and drug discovery research support
First written in FY2016. 1 of 3 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2017.
The whole theme swung hardest in 2026: 2 of 8 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
- FY2017RestatedAnnual report
「株式会社アスクレップ has made various investments and carried out M&A, including making 株式会社京都コンステラ・テクノロジーズ, which possesses cutting-edge computational science and technology, a subsidiary.」
The capital relationship with 京都コンステラ・テクノロジーズ was advanced to the acquisition of a subsidiary, and this has been reiterated as an investment achievement in the healthcare field. - FY2017-Q2AdvancedAnnual report
「During the third quarter consolidated accounting period, the company acquired shares in 株式会社京都コンステラ・テクノロジーズ and included it in the scope of consolidation.」
The company acquired shares in an existing capital and business alliance partner and brought it into the scope of consolidation, further advancing the capital relationship in safety information services and drug discovery research support. - FY2016First statedAnnual report
「At 株式会社アスクレップ, we entered into a capital and business alliance with 株式会社京都コンステラ・テクノロジーズ and strengthened the relationship by expanding safety information services and collaborating in support of drug discovery research.」
The company is expanding healthcare-related services and advancing collaboration in support of drug discovery research through the capital and business alliance.